within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR24_LamivudineTenofovirDisoproxilAndDoravirine;

model LamivudineTenofovirDisoproxilAndDoravirine
  extends Pharmacolibrary.Drugs.ATC.J.J05AR24;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fixed-dose combination of antiretrovirals used for the treatment of HIV-1 infection in adults and adolescents. Each drug acts at different steps in the viral lifecycle: lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI), and doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). The combination is approved and used as a complete regimen for HIV management.</p><h4>Pharmacokinetics</h4><p>Estimated mean pharmacokinetic parameters for healthy adults at steady state following single oral administration of fixed-dose combination tablet containing lamivudine 300mg, tenofovir disoproxil 300mg, and doravirine 100mg.</p><h4>References</h4><ol><li><p>Yee, KL, et al., &amp; Iwamoto, M (2020). Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate. <i>AAPS PharmSciTech</i> 21(3) 91–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-020-1630-6&quot;>10.1208/s12249-020-1630-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32060665/&quot;>https://pubmed.ncbi.nlm.nih.gov/32060665</a></p></li><li><p>Molina, JM, et al., &amp; Hwang, C (2018). Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>The lancet. HIV</i> 5(5) e211–e220. DOI:<a href=&quot;https://doi.org/10.1016/S2352-3018(18)30021-3&quot;>10.1016/S2352-3018(18)30021-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29592840/&quot;>https://pubmed.ncbi.nlm.nih.gov/29592840</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LamivudineTenofovirDisoproxilAndDoravirine;
